ARQT logo

ARQT
Arcutis Biotherapeutics Inc

2,461
Mkt Cap
$2.93B
Volume
1.38M
52W High
$31.77
52W Low
$12.42
PE Ratio
-167.41
ARQT Fundamentals
Price
$24.17
Prev Close
$23.42
Open
$23.81
50D MA
$23.76
Beta
1.43
Avg. Volume
1.05M
EPS (Annual)
-$0.1269
P/B
15.24
Rev/Employee
$1.06M
$3,587.81
Loading...
Loading...
News
all
press releases
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Given Average Recommendation of "Moderate Buy" by Brokerages
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) has earned a consensus rating of 'Moderate Buy' from the eight brokerages that are covering the firm, MarketBeat.com reports. One...
MarketBeat·16h ago
News Placeholder
More News
News Placeholder
Insider Selling: Arcutis Biotherapeutics (NASDAQ:ARQT) Director Sells 7,144 Shares of Stock
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) Director Howard Welgus sold 7,144 shares of the firm's stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $22.99, for a total value of $164,240.56. Following the completion of the sale...
MarketBeat·21h ago
News Placeholder
Pictet Asset Management Holding SA Buys 74,528 Shares of Arcutis Biotherapeutics, Inc. $ARQT
Pictet Asset Management Holding SA lifted its stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 566.4% during the fourth quarter, according to the company in its most...
MarketBeat·2d ago
News Placeholder
UBS Group AG Boosts Position in Arcutis Biotherapeutics, Inc. $ARQT
UBS Group AG lifted its stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 10.0% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 3,243,432 shares of the company's stock after acquir...
MarketBeat·3d ago
News Placeholder
Kornitzer Capital Management Inc. KS Takes Position in Arcutis Biotherapeutics, Inc. $ARQT
Kornitzer Capital Management Inc. KS bought a new stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) during the fourth quarter, according to the company in its most recent 13F filing...
MarketBeat·3d ago
News Placeholder
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·6d ago
News Placeholder
Jennison Associates LLC Has $196.25 Million Position in Arcutis Biotherapeutics, Inc. $ARQT
Jennison Associates LLC lowered its holdings in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 44.9% during the fourth quarter, according to its most recent Form 13F filing...
MarketBeat·6d ago
News Placeholder
Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know
Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·7d ago
News Placeholder
Arcutis Biotherapeutics (ARQT) Expected to Announce Earnings on Wednesday
Arcutis Biotherapeutics (NASDAQ:ARQT) will be releasing its Q1 2026 earnings after the market closes on Wednesday, May 6. (View Earnings Report at...
MarketBeat·8d ago
News Placeholder
Universal Beteiligungs und Servicegesellschaft mbH Buys 147,586 Shares of Arcutis Biotherapeutics, Inc. $ARQT
Universal Beteiligungs und Servicegesellschaft mbH lifted its position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 170.6% during the fourth quarter, according to the...
MarketBeat·8d ago
<
1
2
...
>

Latest ARQT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.